MedPath

TinCat LGBTQ+ Smoking Cessation Via Asynchronous Telehealth

Not Applicable
Conditions
Tobacco Use Cessation
Tobacco Use Disorder
Interventions
Behavioral: TinCat
Behavioral: Quit.gov program
Registration Number
NCT05499364
Lead Sponsor
University of Texas at Austin
Brief Summary

The purpose of this study is to assess the efficacy of a novel telehealth-based intervention to reduce tobacco use among LGBTQ+ people.

Detailed Description

After being informed about potential risks and screened into the study, patients will be randomized into the treatment or control group. Control group participants will complete 7 sessions based on quit.gov smoking cessation planning. Intervention participants will complete 7 sessions of individualized asynchronous telehealth sessions.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Age 18 and over
  • Live in Greater Austin
  • Identify as LGBTQ+
  • Current smokers
  • High speed internet access
Read More
Exclusion Criteria
  • Exceed screener cutoff for suicide risk
  • Exceed screener cutoff for borderline personality disorder
  • Report current active substance use other than tobacco that interferes with functioning
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TinCatTinCatIndividualized asynchronous telehealth including LGBTQ+ affirming components.
Quit.gov programQuit.gov programGeneric intervention based on quit.gov sessions.
Primary Outcome Measures
NameTimeMethod
Tobacco use11 weeks

Cigarette and vape assessments based on prior research on vaping/smoking:

Cigarette: Today, did you have at least one puff on a cigarette (yes/no) IF YES, THEN How many cigarettes did you smoked (at least one puff) (1-"more than 60").

Vaping: Today, did you use an electronic nicotine delivery system (i.e., a vape containing nicotine), even just one puff? (yes/no) IF YES, THEN How many times they had at least one puff (1 time, 2-5 times, 6-10 times, 11-15 times, 16-20 times, 21-25 times, 26-30 times, 31 or more times).

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath